eligibility_summary
Include: Histologically confirmed, untreated DLBCL, age ≥70 or 60–69 with ECOG 2–4, intolerant to standard frontline (e.g., R‑CHOP/mini), measurable disease, adequate organ function, life expectancy ≥6 months, consent. Exclude: primary CNS lymphoma, prior BTKi, major CV disease (LVEF<50%), abnormal labs, HIV, active HCV, or HBV DNA+, uncontrolled illness/psychiatric, drug allergy, GI malabsorption, pregnant/lactating, recent steroids/anticancer therapy/surgery, CYP3A inhibitor/inducer use.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Prospective, single-arm Phase 2 study testing ZPR in elderly, treatment-naive DLBCL. Interventions and mechanisms: Zanubrutinib—oral small-molecule Bruton’s tyrosine kinase (BTK) inhibitor that blocks B-cell receptor (BCR) signaling to suppress malignant B-cell proliferation/survival, Polatuzumab vedotin—anti-CD79b antibody-drug conjugate delivering MMAE to CD79b+ B cells, disrupting microtubules and inducing apoptosis, Rituximab—anti-CD20 monoclonal antibody depleting B cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct apoptosis. Targets: malignant B cells expressing CD79b and CD20, BTK/BCR pathway, microtubule cytoskeleton, immune effector mechanisms.